Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434856 | 0.83 | MAOB (0.50) | MAOBMAOAADORA3ADORA2AADORA1 | |
| SCHEMBL20078226 | 0.81 | MAOA (0.48) | MAOBMAOAADORA3ADORA2AADORA1 | |
| SCHEMBL13979677 | 0.81 | CYP2D6 (0.56) | MAOBMAOACYP2D6TYMPTLR8 | |
| SCHEMBL19756708 | 0.79 | AHR (0.40) | CYP2D6TLR8 | |
| SCHEMBL3883498 | 0.79 | MAOB (0.41) | MAOBMAOACHRM2CHRM4CHRM5 | |
| SCHEMBL14048145 | 0.79 | NPC1 (0.50) | MAOBMAOACYP2D6TLR8 | |
| SCHEMBL1287389 | 0.79 | CA12 (0.45) | MAOBMAOACYP2D6TLR8 | |
| SCHEMBL16795612 | 0.79 | MAOB (0.46) | MAOBMAOAADORA3ADORA2AADORA1 | |
| SCHEMBL348215 | 0.77 | LMNA (0.54) | ADORA3ADORA2AADORA1 | |
| SCHEMBL2056169 | 0.77 | CYP2D6 (0.37) | CYP2D6TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | MAOB 3091/4885MAOA 3545/4885ADORA3 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.